FEB 24, 2016 5:00 AM PST

How Personalised Healthcare is transforming drug development

Speaker
  • VP and Head of Personalised Healthcare and Biomarkers, AstraZeneca
    Biography
      Ruth March, VP and Head of Personalised Healthcare and Biomarkers, leads AstraZeneca's function of world class diagnostic and biomarker science experts, delivering companion diagnostic tests to target AZ drugs to the right patients across each therapy area and all phases of development. She has driven adoption of Personalised Healthcare approaches by 70% of AstraZeneca's pipeline, partnering with a strategic network of diagnostic companies to ensure delivery to global clinical trials and marketed products.

      Ruth spent ten years in immunology and genetics research at the Universities of London and Oxford. She has over 40 publications and patents in the field of pharmacogenomics and Personalised Healthcare and serves as an expert evaluator for the European Commission.

    Abstract

    Personalised Healthcare is essential to AstraZeneca’s approach to drug development and is adopted by more than 80% of drug products in clinical development. Selection of the right patient population using companion diagnostics is integral to the way in which AstraZeneca focuses on quality and innovation. We will discuss examples where Personalised Healthcare has transformed the delivery of new therapies to patients. We will examine how emerging diagnostic science has the potential to improve patient outcomes; including circulating tumour DNA, next generation sequencing and expanding the benefits of Personalised Healthcare across all therapy areas. Finally we will consider the role of partnerships to delivering Personalised Healthcare into clinical practice. We believe that Personalised Healthcare is the future of drug development; it epitomizes what science can do.
     
    Learning objectives:

    • Describe how Personalised Healthcare been used to help transform AstraZeneca’s approach to drug development
    • Understand examples of the use of Personalised Healthcare to develop novel therapies
    • Evaluate the role of emerging diagnostic science to deliver benefit to patients

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    Loading Comments...
    Show Resources